12 Results

People

  1. Zelenetz
    Zelenetz
  2. Moskowitz
    Moskowitz
  3. Portlock
    Portlock
  4. Noy
    Noy
  5. Hamlin
    Hamlin
  6. Horwitz
    Horwitz
  7. Yahalom
    Yahalom
  8. Moskowitz
    Moskowitz
  9. Palomba
    Palomba
  10. Matasar
    Matasar

Groups

  1. Center for Hematologic Malignancies (12)
  2. Department of Medicine (12)
  3. Hematologic Malignancies, Division of (12)
  4. Lymphoma (12)
  5. Population Sciences Research Program (8)
  6. Radiation Oncology, Department of (7)
  7. Radiology, Department of (7)
  8. Survivorship Research (7)
  9. Biostatistics Service (6)
  10. Epidemiology and Biostatistics (6)
  1. "ifosfamide"
  2. "Paul Hamlin"
  3. "David Straus"
Formats
  1. Journal Article (12)
Groups
  1. Center for Hematologic Malignancies (12)
  2. Department of Medicine (12)
  3. Hematologic Malignancies, Division of (12)
  4. Lymphoma (12)
  5. Population Sciences Research Program (8)
  6. Radiation Oncology, Department of (7)

More Groups

People
  1. Andrew Zelenetz (12)
  2. David Straus (12)
  3. Paul Hamlin (12)
  4. Carol Portlock (10)
  5. Craig Moskowitz (10)
  6. Ariela Noy (9)

More People

Years
  1. 2024 (1)
  2. 2020 (1)
  3. 2017 (1)
  4. 2015 (1)
  5. 2012 (1)
  6. 2010 (2)

More Years

Publications
  1. British Journal of Haematology (4)
  2. Blood (3)
  3. Annals of Oncology (1)
  4. Blood Advances (1)
  5. Haematologica (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (4)
  2. John Wiley & Sons (4)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Science, Inc. (1)
  5. Ferrata Storti Foundation (1)
  6. Oxford University Press (1)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Nimer, S. D.; Gerecitano, J.; Hamlin, P.; Horwitz, S.; Moskowitz, A. J.; Noy, A.; Palomba, L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging: Research paper
    Journal Article

    Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Zhang, Z.; Filippa, D.; Teruya-Feldstein, J.; Kewalramani, T.; Moskowitz, A. J.; Rice, R.; Maragulia, J.; more...
    British Journal of Haematology (2010)

    Fulltext@MSK | Save
  • Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma
    Journal Article

    Moskowitz, C. H.; Schoder, H.; Teruya-Feldstein, J.; Sima, C.; Iasonos, A.; Portlock, C. S.; Straus, D.; Noy, A.; Palomba, M. L.; O'Connor, O. A.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
    Journal Article

    O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Journal Article

    O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumitrescu, O.; Colevas, A. D.; Grant, B.; Zelenetz, A.
    British Journal of Haematology (2008)

    Fulltext@MSK | Save
  • Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Journal Article

    O'Connor, O. A.; Hamlin, P. A.; Portlock, C.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; more...
    British Journal of Haematology (2007)

    Fulltext@MSK | Save